The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial.
V. Stearns
Honoraria - AstraZeneca
Research Funding - Abraxis BioScience; Merck; Novartis; Pfizer
J. W. Chapman
No relevant relationships to disclose
C. X. Ma
No relevant relationships to disclose
M. J. Ellis
Consultant or Advisory Role - AstraZeneca; Novartis; Pfizer
Research Funding - AstraZeneca; Novartis
Other Remuneration - AstraZeneca; Novartis; Pfizer
J. N. Ingle
Other Remuneration - Pfizer
K. I. Pritchard
Consultant or Advisory Role - Abraxis BioScience; Amgen; Boehringer Ingelheim; Novartis; Pfizer; Roche
Honoraria - Abraxis BioScience; Boehringer Ingelheim; Novartis; Pfizer; Roche
Expert Testimony - AstraZeneca; Novartis
G. T. Budd
Consultant or Advisory Role - AstraZeneca; Pfizer
M. Rabaglio
No relevant relationships to disclose
G. W. Sledge
No relevant relationships to disclose
A. Le Maitre
No relevant relationships to disclose
J. Kundapur
No relevant relationships to disclose
L. E. Shepherd
No relevant relationships to disclose
P. E. Goss
Honoraria - GlaxoSmithKline; Novartis; Pfizer